D&D Pharmatech Initiates Phase 2 Trial For Obesity Treatment DD01
21 Aug 2024 //
BUSINESSWIRE
D&D Granted Fast Track Designation from FDA for DD01 for the NASH/MASH
02 Apr 2024 //
BUSINESSWIRE
D&D Pharmatech Announces Rapid, Clinically Significant Reductions in Liver Fat
02 May 2023 //
BUSINESSWIRE
Neuraly points to younger patients as Parkinson`s bet fails
27 Mar 2023 //
FIERCE BIOTECH